Vivostat® PRF

platelet enriched fibrin

Vivostat® PRF

The presence of growth factors is essential to the process of tissue regeneration (e.g. soft tissue, connective tissue, muscle and bone). By combining a platelet concentrate with a fibrin sealant, it is possible to have a carrier, a controlled release, and a medium for tissue in-growth – all in one product; Vivostat® PRF.

Platelets and growth factors have been used for many years to help regenerate tissue and stimulate bone formation, often as a traditional thrombocyte solution supplied by the blood bank. Later, a number of commercial products entered the market with simpler and smaller devices based on the same centrifugation technology. Most products required sterile handling and have shortcomings in both the biophysical properties and the delivery system.

Vivostat® solved these problems by leveraging the revolutionary technology used in the Vivostat® System for the preparation and application of autologous fibrin sealant. Our autologous reproduceable combination of a platelet concentrate and a fibrin sealant solution is simply unique.

Products characteristics

Clinical studies have demonstrated the beneficial effect of combining a platelet concentrate with a high concentration of fibrin. The Vivostat® System is the first and only system on the market to offer a convenient and fully automated process for the preparation of such matrices.

Vivostat® PRF contains a variety of potent growth factors that stimulate fibroblast proliferation and tissue synthesis, e.g. TGF-β1,PDGF, VEGF, FGF-2 etc. Several in-vitro investigations confirm the unique characteristics of Vivostat® PRF and its ability to stimulate cell growth.

Fibroblasts are fundamentally important in the process of tissue repair. Apart from producing structural proteins such as collagen, they stimulate both angiogenesis and epithelialisation. In-vitro studies have proven the positive effect of Vivostat® PRF on fibroblast proliferation. As illustrated, Vivostat® PRF increases the growth of normal human skin fibroblasts compared to control and performs significantly better than PDGF-BB (commercial growth factor).
Collagen deposition is an essential component in the wound healing cascade. In-vitro studies have illustrated the positive effect of Vivostat® PRF on the ability of fibroblasts to synthesise collagen. Vivostat® PRF performs better than PDGF-AB, the major PDGF isoform in human platelets. The reason for this may be that Vivostat® PRF contains multiple growth factors and not just PDGF-AB.

The use of Vivostat® PRF in e.g. wound care or surgical procedures is largely dependent on the effect and stability of the platelet rich fibrin derived growth factors. Controlling the release of platelet contents over several days requires not only a delivery media but also protection of the platelets against degradation. The autologous fibrin matrix in Vivostat® PRF has shown to protect endogenous growth factors against proteolytic degradation and thereby preserve their biological activity.

Vivostat® PRF delivers a concentrate of growth factors embedded in a autologous fibrin matrix. Following application of the Vivostat® PRF solution, the fibrin matrix will naturally be broken down by fibrinolytic processes (fibrinolysis), and during this process the growth factors contained in the platelets are gradually released to the treatment site over a period of 4 days or more. In effect, the matrix is a delivery media that slowly releases growth factors over time.

What is
Vivostat® PRF

Growth factors and fibrin are essential components when it comes to regeneration of tissue. Using the Vivostat® System, you can prepare autologous platelets with multiple growth factors embedded in a matrix. From 120 ml blood, 5-6 ml of platelet rich fibrin (PRF) is prepared. By combining a platelet concentrate with a fibrin sealant solution, it is possible to have a carrier, a controlled release and a medium for vascular ingrowth – all in one product, Vivostat® PRF.

Compared to conventional PRP products, Vivostat® PRF has a number of advantages.

With an average 7-fold increase over baseline blood levels, the platelet concentration in Vivostat® PRF exceeds the baseline platelet count of 1 million/μL, which has become a benchmark within platelet therapy. The fibrin matrix ensures a slow release of growth factors over time and effectively protects the growth factors against proteolytic degradation.
The specially designed Vivostat® Spraypen and the unique combination of platelets and fibrin ensures easy, accurate and efficient application of Vivostat® PRF. Due to instant polymerisation and excellent adhesive properties of the fibrin component, the Vivostat® PRF matrix remains where it is applied – even when applied on vertical or inverted surfaces. As the fibrin component in Vivostat® PRF is based on a fibrin 1 solution, there is no need to use a separate thrombin component. Naturally utilising the combination of platelets and fibrin sealant has many more benefits.
Play Video

A revolution in tissue regeneration

Vivostat® PRF is first generation platelet rich fibrin matrix from Vivostat® – however still going strong. Unlike our other matrices, Vivostat® PRF is not targeted a specific indication; it can be used for all surgical applications where platelet rich fibrin is needed. Click on the video to see how Vivostat® PRF is used in a liver transplant surgery.

Product order codes vivostat® PRF

General surgery

The ability to use the Vivostat® Endoscopic Applicator in general surgery has proven very useful.

Wound treatment

The unique combination of platelets and fibrin in our products makes it perfect in treating challenging wounds.

  1. Lundquist, R., Dziegiel, M. H., & Agren, M. S. (2008), Bioactivity and stability of endogenous fibrogenic factors in platelet-rich-fibrin, Wound Repair Regeneration official pulication of the wound Healing Society and the European Tissue Repair Society, 16(3), 356–363, https://doi.org/10.1111/j.1524-475x.2007.00344.x
  2. Scherer, S., Tobalem, M., Vigato, E., Heit, Y. I., M, A., Hinz, B., Pittet, B., & Pietramaggiori, G. (2012), Nonactivated versus thrombin-activated platelets on wound healing and fibroblast-to-myofibroblast differentiation in vivo and in vitro, Plastic Reconstructive Surgery ee, 129(1), 46e–54e,  https://doi.org/10.1097/prs.0b013e3182362010